2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Matthew Ellis from Washington University on Anticipated ER-positive/HER2-negative Breast Cancer Paradigms
Matthew J. Ellis, MD, PhD, director, Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, MO, explains that he anticipates a paradigm between other rare forms of cancer and estrogen receptor (ER) positive/HER2-negative breast cancer.
Ellis hopes to find something similar to the use of imatinib for Ph+ CML. In this case a fusion gene, BCR-ABL, activates the tumor cells, by inhibiting the mutation you can get rid of the tumor. In breast cancer an example would be Herceptin and other agents for HER2 amplifications.